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Abstract
In kidney transplant recipients, cancer is one of the leading causes of death with a functioning graft beyond the first year
of kidney transplantation, and malignancies account for 8–10% of all deaths in the USA (2.6 deaths/1000 patient-years)
and exceed 30% of deaths in Australia (5/1000 patient-years) in kidney transplant recipients. Patient-, transplant- and
medication-related factors contribute to the increased cancer risk following kidney transplantation. While it is well
established that the overall immunosuppressive dose is associated with an increased risk for cancer following
transplantation, the contributive effect of different immunosuppressive agents is not well established. In this review
we will discuss the different risk factors for malignancies after kidney transplantation.
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Introduction
Malignancy is one of the most common causes of death in kid-
ney transplant recipients [1, 2]. In kidney transplant recipients,
the incidence of cancer is generally increased 2- to 3-fold com-
pared with the general population [3, 4]. This increased cancer
risk is not spread evenly over all types of cancers; while some
cancer incidences are not increased (breast, prostate, ovarian,
brain and cervical cancer), others are increased substantially
(lung, colon, liver, lymphoma, melanoma and non-melanoma
skin cancer). Cancer-related mortality rates are also higher in
kidney transplant recipients compared with the general popu-
lation [5].
Patient-, transplant- and medication-related factors contrib-
ute to the increased cancer risk following kidney transplanta-
tion. Immunosuppression is considered the most important
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risk factor, as it decreases the immunologic control of oncogenic
viral infection and cancer immunosurveillance [4, 6]. Although
it is accepted that the overall immunosuppressive dose is asso-
ciated with the increased cancer risk following transplantation,
the contributive effect of different immunosuppressive agents
is not well established at this time. Currently available immu-
nosuppressive agents influence different anticancer pathways
and mammalian target of rapamycin (mTOR) inhibitors have
been reported to have a decreased cancer risk compared with
alternative immunosuppressive therapies. However, recent
studies have not been able to demonstrate improved survival in
kidney transplant recipients taking mTOR inhibitors. T cell–
depleting agents are very potent immunosuppressive agents
used as induction therapy and to treat acute rejection (AR) in
kidney transplant recipients. While some studies have sug-
gested an association between antibody induction and cancer
after transplantation [7–11], others have failed to demonstrate
this association [12–15].
Epidemiology and clinical presentation
Analyses from different registry data estimate the general increase
in cancer incidence in kidney transplant recipients to be two- to
three-fold compared with the general population [3, 4, 16–25].
Estimates of cancer incidence obtained from different registries
differ widely, suggesting that data quality is problematic. This was
confirmed in a recent study by Yanik et al. [26], who compared can-
cer diagnoses collected in the Scientific Registry of Transplant
Recipients (SRTR) database with 15 linked cancer registries for col-
orectal, liver, lung, breast, prostate and kidney cancers, melanoma
and non-Hodgkin lymphoma (NHL). They concluded that SRTR
cancer data were strikingly incomplete, as only 36.8% of cancers
were both registered in the SRTR database and cancer registries,
whereas 47.5% of cancers were only documented in cancer regis-
tries and 15.7% were only documented in the SRTR database [26].
The estimated sensitivity for identifying cancer was only 52.5% for
the SRTR and 84.3% for cancer registries [26].
Data from the USA concerning 175 732 solid organ transplant
recipients (58.4% kidney transplant recipients) during the period
1987–2008 showed that the standardized incidence ratio (SIR)
for cancer overall was 2.1 (95% CI 2.06–2.14) higher compared
with the general population, with an excess absolute risk of 719
cancer cases per 100 000 person-years [3]. The majority of the
patients included in these studies were kidney transplant recipi-
ents [27]. It is important to note that this increase is not uniform
for all cancer types; some cancers are not increased following
kidney transplantation, e.g. breast, prostate, ovarian, cervical and
brain cancers [3, 4, 20], and the incidence of breast cancer might
even be reduced [3, 28]. In contrast, lymphoma, lung cancer,
colon cancer, melanoma and non-melanoma skin cancer and
liver cancer are increased 2- to 4-fold. In a study by Engels et al.
[3], skin cancer was the most common malignancy in solid organ
transplant recipients, with a SIR for Kaposi sarcoma and non-
melanoma skin cancer of 61.46 and 13.85, respectively. In addi-
tion, the SIRs for non-Hodgkin and Hodgkin lymphoma, liver can-
cer, gastrointestinal cancer and melanoma were also increased
[3]. In more recent reports from both the Australia and New
Zealand Dialysis and Transplant Registry (ANZDATA) registry
[29] and European and North American registries [23], excluding
non-melanocytic skin cancers, genitourinary tract cancers are
the most frequent malignancies in renal transplant recipients.
In an analysis of the Collaborative Transplant Study (CTS)
database, the incidence and impact of malignant lymphoma
after solid organ transplantation in 195 938 solid organ
transplant recipients (145 104 cadaveric kidney transplant recip-
ients) between 1985 and 2001 were studied [30]. Over the 10-
year observation period, the risk for malignant lymphoma in
renal transplant recipients was 11.8-fold higher compared with
a matched non-transplanted population, and most lymphomas
occurred in the first post-transplant year [30]. Recent data sug-
gest that from 2005 to 2010, the 5-year incidence of post-
transplant lymphoproliferative disease (PTLD) in adult kidney
transplant recipients has remained stable [31]. There was, how-
ever, a substantial decline in PTLD rates for paediatric recipients
reported in patients transplanted from 2002 to 2012 compared
with those transplanted from 2000 to 2009 [31]. In all groups,
PTLD risk was highest in Epstein–Barr virus (EBV)-seronegative
recipients [31]. In kidney transplant recipients, there is a slight
predilection for the lymphoma to occur in the transplanted kid-
ney. In addition, central nervous system lymphomas were most
common after renal transplantation in the CTS [30].
On average, the age at diagnosis of post-transplant cancer is
40 years and the time from transplantation is 3–5 years [12, 28,
32]. However, these numbers vary substantially according to the
cancer subtype, with lymphoma and Kaposi sarcoma occurring
early after transplantation [30, 33] and epithelial cancers later on
[33, 34]. Although in other types of solid organ transplantation
cancer tends to occur in the transplanted organ, in kidney trans-
plant recipients, kidney cancers almost exclusively occur in the
native kidneys [1] and there is a greater incidence of papillary
type relative to the general population [35]. Acquired cystic kid-
ney disease is common in patients with advanced renal failure
and is associated with the development of kidney cancer [25, 36].
In dialysis patients, the risks for thyroid cancer, myeloma and
urinary tract cancers are increased, and this is mirrored in kidney
transplant recipients [25]. This parallel between dialysis patients
and kidney transplant recipients does not hold true for all cancer
types, as ovarian and prostate cancer were less frequent in kid-
ney transplant recipients than in the dialysis cohorts [23].
Pathogenesis and transplant-specific risk
factors
Several factors have been linked to the increased incidence of
malignancies among transplant recipients [6], including age,
sun exposure, previous cancer, concomitant viral infection,
cumulative dose of immunosuppression, type of immunosup-
pression, AR and the duration of pre-transplant dialysis (Table 1
and Figure 1) [38, 39]. Risk factors for patient death from
cancer include male gender, a history of prior cancer and
immunosuppression and lymphocyte-depleting antibodies [5].
Donor transmission
A variety of donor-transmitted malignancies have been docu-
mented, including melanoma and cancers of the lung, breast,
colon, rectum and kidney, Kaposi sarcoma and glioblastoma
multiforme. Donor transmission as a cause of post-transplant
malignancy is a rare but dreaded event, as it might result in
metastatic disease in the transplant recipient [40–47]. Reported
transmission rates are <0.03%, but these are likely under-
reported and underdiagnosed [41, 48, 49]. The most common
transmitted cancer types are renal cancer, lung cancer, mel-
anoma and lymphoma [46, 50, 51]. The risk of donor transmis-
sion depends on the type and extent of the original donor
cancer. A donor history of melanoma, lung carcinoma or chorio-
carcinoma seems to be associated with high transmission risk
and death and organs from such donors should not be accepted
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for transplantation [46]. In contrast, organs from donors with
renal cell cancer without capsular invasion and central nervous
system tumours (except medulloblastoma) are acceptable, as
the risk seems to be low, reflecting the limited metastatic
potential of these tumours [46, 52]. Regarding outcome, early
donor-transmitted cancer (diagnosed 6 weeks of transplanta-
tion) was associated with a better outcome compared with late
donor-transmitted cancer [51]; 5-year survival was 83% for kid-
ney recipients with donor-transmitted cancer compared with
93% for recipients without donor-transmitted cancer (P¼ 0.077)
[50, 51]. Recipients with transmitted renal cancers had the best
outcomes, with >70% 2-year survival post-transplantation [50],
while patients with melanoma and lung cancers had <50% 2-
year survival post-transplantation [50].
Donor type
Differences in the type of transplant (living versus deceased)
have been associated with cancer risk. In a study by Ma et al.
[53], the overall risks for cancer were 1080, 1444 and 2018 per
100 000 patient-years for recipients of living donor, standard
and expanded criteria deceased donor kidney recipients,
respectively. This increased risk with different donor types was
independent of age, sex, and time on dialysis [53]. Recipients of
living-donor kidneys had a lower risk of cancer, particularly for
genitourinary cancer and PTLD [53].
Recipient age and time on dialysis
Both in paediatric and adult kidney transplant recipients, recipi-
ent age has been identified as an independent risk factor of
post–kidney transplant malignancies [54, 55]. With increasing
recipient age, this is an important factor in the overall increas-
ing incidence of post-transplant cancer in kidney transplant
recipients. Time on dialysis before transplantation has also
been identified as a risk factor for developing post-transplant
malignancy. In a study based on the ANZDATA database, Wong
et al. [38] reported a linear relationship between the duration of
dialysis and the risk of solid organ cancer after transplantation,
irrespective of recipient age. In a very interesting article, Yanik
et al. [56] evaluated the incidence of cancer types depending on
non-renal function interval (time on dialysis either on wait list
or after transplant failure) or kidney function interval (time
with a functioning graft and thus on immunosuppression),
applying a linkage between the SRTR and several US cancer
registries. While the incidence of infection-related and
immune-related cancer (Kaposi sarcoma, NHL, lip cancer and
non-epithelial skin cancer) was higher during kidney function
intervals, end-stage renal disease (ESRD)-related cancer inci-
dence (kidney cancer and thyroid cancer) was lower during kid-
ney function intervals. Every change of status (non-renal
function interval/kidney function interval) was associated with
a changing incidence for NHL, melanoma, lung, pancreatic and
non-epithelial skin cancers (higher during function intervals)
and kidney and thyroid cancers (higher during non-function
intervals), suggesting potent short-term effects of kidney dys-
function and immunosuppression on cancer incidence [56].
Previous cancer
A history of cancer prior to kidney transplantation in the recipi-
ent increases the risk of death by 30% [57].These findings were
also confirmed in another study showing that kidney transplant
recipients with a pre-transplant cancer are 3.7 times more likely
to die of cancer post-transplantation [5]. Acuna et al. [58] per-
formed an interesting meta-analysis including 32 cohort studies
on solid organ transplant recipients with a pre-transplant
malignancy in remission. They demonstrated that pre-trans-
plant malignancy is associated with an increased risk of all-
cause mortality (pooled hazard ratio 1.51), cancer-specific mor-
tality (pooled hazard ratio 3.13) and of developing de novo malig-
nancies (pooled hazard ratio 1.92) after transplantation
compared with solid organ transplant recipients without a pre-
transplant malignancy [58]. These studies clearly identify kidney
transplant recipients with pre-transplant cancer as a high-risk
Fig. 1. Cancerogenesis following kidney transplantation (adapted from Riella [37]).
Table 1. Risk factor for post-transplant malignancies
Patient-related risk factors Recipient age
Previous cancer
Sun exposure
Viral infection
Duration of dialysis
Transplant-related risk factors Donor transmission
Donor type
Rejection
Medication-related risk factors Net immunosuppression
Induction therapy
Maintenance therapy
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patient population requiring tailored screening and management
strategies.
Organ predilection
The incidence of specific malignancies varies according to the
transplanted organ [3]. While in some types of transplantation
(lung and liver), post-transplant malignancies tend to occur in
the transplanted organ, in kidney transplantation this does not
appear to be the case (kidney cancer in kidney transplant recipi-
ents primarily affects the native kidney) [3, 4, 16–23]. In addi-
tion, other cancer types vary depending on the transplanted
organ. For example, the risk of NHL in lung transplant recipients
is doubled compared with kidney, heart or liver transplant [3].
It is well established that kidney cancer is greatly increased
in dialysis patients and kidney transplant recipients [3, 4, 16–
23]. Prolonged time on dialysis has been identified as a risk fac-
tor for the development of kidney cancer [59, 60] and the inci-
dence of kidney cancer can be as high as 100 times the expected
incidence [61, 62]. While kidney cancer in native kidneys is fre-
quent, cancer in the transplanted kidney is rare. In a European
retrospective study, 20 patients were identified with kidney
cancer in the transplanted kidney: 85% were papillary renal cell
carcinoma (RCC) and 15% were clear cell RCC [63]. The tumours
were small at the time of diagnosis and all patients were man-
aged with ablation therapy (cryoablation or radiofrequent abla-
tion) without a reduction or change in their immunosuppressive
therapy [63].
Sun exposure
In the development of skin cancer, sun exposure is an estab-
lished risk factor [64–66]. The application of sun block and
administration of nicotinamide have both been demonstrated
to reduce the incidence of non-melanoma skin cancer [67–70].
Viral infection
At least four viruses are believed to be co-carcinogenic in trans-
planted patients: EBV (Hodgkin’s and NHL), human herpesvirus
8 (HHV8; Kaposi sarcoma) [71–73], human papillomavirus (HPV;
cervix, vulva, vagina, anus and some oro-pharynx cancers) and
Merkel cell polyomavirus (Merkel cell skin carcinoma). EBV has
conclusively been implicated in the pathogenesis of PTLD fol-
lowing kidney transplantation [74, 75] and EBV status is one of
the most important risk factors for PTLD. More than 50% of
PTLD cases are EBV related, and EBV mismatch between donor
and recipient (an EBV-negative receptor engrafted with an EBV-
positive donor) is associated with a 20-fold increased risk for
PTLD [76–78]. Moreover, primary EBV infection post-transplant
is a major risk factor for EBV-positive PTLD in early onset PTLD
[15]. Additionally, other viruses have been associated with the
development of cancer, e.g. hepatitis B and C (HBV and HCV;
liver cancer) and BK polyomavirus (urological cancers) [79–87].
The central role of the immune system in the control of onco-
genic viruses was emphasized by the findings of Grulich et al.
[4], where a similar increase of virus-associated cancers was
observed in solid organ transplant patients and patients with
HIV/AIDS. As far as cytomegalovirus (CMV) and post-transplant
malignancy are concerned, conflicting results have been
reported [88–92], so at this time it is not clear whether CMV
infection is associated with an increased risk of post-transplant
cancer. A recent study demonstrated that cancer risk after kid-
ney transplantation during childhood is particularly increased
for virus-related cancers [54].
Rejection and treatment
As the total dose of immunosuppression is related to the risk of
post-transplant malignancy, it is no surprise that rejection epi-
sodes and anti-rejection therapy are associated with the risk of
post-transplant malignancy, as doses of maintenance immuno-
suppression including calcineurin inhibitors, antimetabolite
and/or corticosteroids are often increased during the treatment
of rejection, thereby contributing to increased T cell dysfunction
[93]. Besides T cell dysfunction, systemic inflammation and
concomitant release of cytokines and chemokines may promote
malignant transformation [94, 95]. In the CTS, anti-rejection
therapy with OKT3 or anti-thymocyte globulin (ATG) increased
the overall cancer risk [96]. In a recent analysis of the
ANZDATA, Lim et al. [29] studied the risk of incident cancer
among kidney transplant recipients who have experienced AR,
stratified by the use of T cell–depleting antibodies. The study
included 7153 kidney transplant recipients transplanted
between 1997 and 2009, of which 6.5% developed cancers. The
risk for cancer after first kidney transplantation was signifi-
cantly higher in patients experiencing AR treated with T cell–
depleting antibodies (adjusted hazard ratio 1.42) compared with
kidney transplant recipients not experiencing AR and the excess
cancer risk was mainly confined to genitourinary tract cancers
[29]. Also, treatment of rejection with high-dose steroids can
adversely affect the risk for PTLD [97].
Maintenance immunosuppression
Maintenance immunosuppression is essential after kidney
transplantation to prevent allograft rejection. Although it is
accepted that overall immunosuppression dose is associated
with an increased cancer risk following transplantation, the
contributive effect of different immunosuppressive agents is
not established. The mechanisms linking immunosuppression
dose to the increased incidence of cancer are numerous and
include decreased immune surveillance of tumours, decreased
antiviral responses resulting in a specific increase of virus-
induced tumours and possibly the direct carcinogenic effect of
immunosuppressive drugs such as cyclosporine and azathio-
prine (Table 2) [6].
The cumulative immunosuppressive dose (net immunosup-
pressive dose for the entire life) is associated with the risk for
cancer post-transplant. For example, patients previously treated
with immunosuppression for primary glomerular disease [128] or
for AR [29] are at higher risk to develop cancer. Hibberd et al. [128]
reported an association between pre-transplantation immuno-
suppression and increased risk for four cancer groups: anogenital
cancer, NHL, breast cancer and urinary tract cancer (excluding
kidney). Grulich et al. [4] analyzed seven studies of people with
HIV/AIDS (n¼ 444 172) and five of transplant recipients
(n¼ 31 977) for 20 of the 28 types of cancers. A significantly
increased cancer incidence was found in both populations, and
most cancers that occurred at increased rates involved oncogenic
viruses (e.g. EBV, HHV8, HPV, HBV and HCV). The rates of most
common epithelial cancers (breast or prostate cancer) were not
increased [4]. The similarity of the pattern of increased risk of
cancer in the two populations suggests that it is immune defi-
ciency rather than other risk factors for cancer that is responsible
for the increased risk. Of note, there were also some discrepan-
cies noted, as some cancer types (thyroid, kidney, melanoma and
bladder cancers) were increased in the transplant population but
not in the HIV/AIDS cohorts.
Although results suggest that currently available immuno-
suppressive agents influence different anticancer pathways
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[101], it is not clear whether currently used medications such as
cyclosporine, tacrolimus, azathioprine or mycophenolate are
associated with different cancer risks [14, 129–131]. mTOR inhib-
itors have been reported to have less cancer risk compared with
alternative immunosuppressive therapies [132]; however, in a
recent systematic review, decreased cancer incidence in kidney
transplant recipients treated with mTOR inhibitors did not
result in improved overall survival [133]. As induction therapy is
concerned, interleukin-2 (IL-2) receptor antagonist (IL-2Ra)
induction does not appear to be associated with an increase in
cancer [39], whereas some studies find a small increase in can-
cer and cancer death with lymphocyte-depleting antibodies [5,
134, 135]. Moreover, there appear to be differences in the differ-
ent types of lymphocyte-depleting antibodies.
Induction therapy
Multiple agents have been used as induction therapy at the
time of kidney transplantation [e.g. OKT3/muromonab, polyclo-
nal lymphocyte-depleting antibodies, anti-IL-2 receptor (CD25)
antibodies and alemtuzumab (anti-CD52). As both CD4þ and
CD8þ T cells are crucial in adaptive antiviral immunity,
depletion of both populations of T cells with T cell–depleting
antibodies would increase the susceptibility of individuals to a
higher risk of virus-associated diseases [136]. Direct anti-
tumour effects have also been attributed to CD4þ T helper 1
cells, CD8þ cytotoxic T cells and natural killer (NK) cells [137].
Polyclonal T cell–depleting antibodies target a variety of T and
NK cell-derived antigens, including CD2, CD3, CD4, CD8 and
CD16, but also markers expressed by leucocytes, B cells and
plasma cells, which may explain the predisposition to infec-
tions and cancer complications associated with the use of these
agents [138–140].
The immunosuppressive potency of OKT3 is greater than
that of polyclonal lymphocyte–depleting agents and the use of
OKT3 has clearly been associated with an increase in lymphoma
risk [14, 141–143]. OKT3 is no longer commercially available, but
other forms of induction therapy are still currently in use and
from the late 1990s onwards, rabbit ATG (rATG) became the
most commonly used polyclonal agent in the USA [144, 145],
and later worldwide [146, 107].
Polyclonal induction therapy: When evaluating the cancer-
inducing effect of different types of polyclonal lymphocyte-
depleting agents, the data are limited and hard to interpret.
Available registry analyses have often combined all polyclonal
lymphocyte-depleting agents into one category and often span
multiple decades. Combining different types of induction
agents (e.g. polyclonal induction agents or ATG) is problematic,
as there are clear differences in the risk of PTLD associated with
different preparations [141, 147]. Furthermore, over time the
type of lymphocyte-depleting agent, the average dose of rATG
and the type and dose of concomitant immunosuppressive
agents have changed significantly. During the 1980s and early
1990s, OKT3 and non-rATG preparations were most widely used
[144, 145], and this was associated with a marked increase in
the incidence of PTLD [148, 149]. From the late 1990s onwards,
rATG became the most commonly used polyclonal agent in the
USA [144, 145], and later worldwide [146]. Finally, in the 1980s
rATG dosing was markedly higher than it is now (e.g. total dose
Table 2. Immunosuppressive drugs and oncogenesis
Immunosuppressant agent Method of action Role in carcinogenesis
Calcineurin inhibitor Inhibition of IL-2 production
through binding and inhibition
of cyclophilin (cyclosporine) and
FKBP-12 (tacrolimus),
respectively
Production of TGF-b [98, 99]
Production of VEGF [98, 100]
Production of interleukin-6 (IL-6) (promotion of EBV-induced B-cell growth)
[101]
Promotion of invasive behaviour of non-transformed cells [98]
Reduced ability to repair radiation-induced DNA damage
Enhanced apoptotic effects of taxol and IFN-c on human gastric and bladder
cancer cells [102, 103]
Increased rate of lymfoproliferative disorders in HSV-infected mice [104]
Azathiopurine Inhibition of DNA and RNA synthe-
sis through incorporation of thi-
opurine analogues
Intercalation at the DNA level, inhibiting repair splicing and eliciting codon
misreads [105]
Increased development of microsatellite DNA instability [106]
Mycophenolate mofetil Inhibition of inosine monophos-
phate dehydrogenase and de
novo purine biosynthesis
Anti-proliferative effect on leukaemia and solid tumour
Inhibition of adhesion molecules [107, 108–114]
Suppressed glycosylation and expression of several adhesion molecules [109,
115]
Inhibition of adhesion of colon adenocarcinoma cells to endothelial cells
[116]
mTOR inhibitors Inhibition of mTOR pathway Direct antitumour effect by inhibition of mTOR pathway [117, 118]
Inhibition of angiogenesis
Inhibition of p70 S6K: decreasing cancer cell proliferation [119, 120
Inhibition of interleukin-10: decreasing tumour cell JAK/STATs activity [120]
Inhibition of cyclins: blocking cell-cycle activity [121]
Decreased VEGF-A and VEGF-C signalling: impaired tumour angiogenesis
[101, 119, 122, 123]
Inhibition of growth signals in PTLD-associated EBV þ B-cell lymphomas [124]
Inhibition of replication of EBV-positive B cells, T cells and NK cells [125, 126]
Inhibition of ultraviolet B–induced metalloproteinase activation [127]
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14 mg/kg versus 6 mg/kg now) [150] and it has been demon-
strated that higher rATG dosing is associated with a higher risk
of PTLD [13].
Earlier studies have suggested an association of induction
therapy with T cell–depleting antibodies with an increased risk
of PTLD. In an analysis of the CTS, the SIR of lymphoma com-
pared with a similar non-transplant population was higher with
T cell–depleting antibody induction as compared with IL-2Ra or
no induction therapy [143]. Also, a study of the SRTR and the
United States Renal Data System databases reported similar
results (70% increased risk of PTLD in renal transplant recipients
receiving monoclonal and/or polyclonal T cell–depleting anti-
bodies as induction therapy) [10, 14]. Also, an earlier analysis of
the ANZDATA registry demonstrated that the use of T cell–
depleting antibodies (as induction or as treatment for rejection)
was associated with a more than two-fold increased risk of
early onset NHL after transplantation [9]. Registry database
studies reported results regarding rATG use and the occurrence
of PTLD have been mixed. Only three studies looked at rATG
specifically and two found an increased risk for PTLD while one
did not [10, 11, 151]. Other registry studies of PTLD risk have
grouped multiple lymphocyte-depleting induction agents
together for the purpose of analysis, in some cases including
OKT3 [14, 152–155]. Three prospective randomized trials fol-
lowed patients up to 5 years after kidney transplantation [156–
158]. The incidence of PTLD and the follow-up time were too
limited to allow for meaningful conclusions [159–162]. Finally, a
systematic review by Marks et al. [13] evaluated the rate of PTLD
in recipients of kidney or heart allografts and pointed to the
importance of antiviral prophylaxis, as in this study; the
absence of antiviral prophylaxis was the greatest risk factor for
the development of PTLD rather than the use of induction
therapy.
IL-2R antagonist induction: In the CTS, induction therapy
with polyclonal and IL-2Ra induction was not associated with
significant increases in the risk of PTLD when compared with
no induction therapy [14]. However, universal use of IL-2Ra
induction is increasingly questioned, as it does not provide ben-
efit in low-risk kidney transplant recipients compared with no
induction therapy, while being inferior compared with ATG in
high-risk kidney transplant recipients [161, 163–165]. In a recent
observation study, rATG was associated with a decreased risk of
adverse outcomes (including mortality) compared with alemtu-
zumab and basiliximab as induction therapy [166].
Alemtuzumab: In the Transplant Cancer Match study, the
use of alemtuzumab as induction therapy was associated with a
79% increase in NHL, a 2.5-fold increase in colorectal cancer and
3-fold increase in thyroid cancer after transplantation [142].
Other studies have reported mixed results regarding the use of
alemtuzumab and PTLD; although one study did not find an
association [11], another using a more recent Organ
Procurement and Transplantation Network cohort did [78]. A
recent study in small bowel allograft recipients receiving alem-
tuzumab demonstrated earlier onset of lymphoplasmacytic
hyperplasia, the most indolent form of B lymphocyte clonal
expansion, compared with patients receiving the IL-2Ra induc-
tion agent daclizumab [167].
Maintenance therapy
Calcineurin inhibitors: In kidney transplant recipients, both
cyclosporine and tacrolimus are associated with an increased
risk of malignancy [101]. In a French prospective randomized
study involving 231 renal allograft recipients, low-dose (75–
125 ng/mL) cyclosporine was associated with a lower incidence
of secondary cancers (particularly skin cancers) compared with
normal-dose (150–250 ng/mL) cyclosporine at a median of
66 months follow-up [168]. Some evidence suggested a higher
risk for PTLD under tacrolimus versus cyclosporine [169, 170].
However, subsequent analyses by the same group postulated
that this was the result of a lack of experience with the agent
and overaggressive dosing at the time of introduction of tacroli-
mus in clinical practice. Ultimately, reduced tacrolimus trough
levels led to substantial declines in the risk of PTLD [171]. An
analysis of the CTS demonstrated that cyclosporine did not con-
fer added risk for the development of NHL compared with aza-
thioprine/steroid treatment, whereas treatment with FK506
increased the risk approximately 2-fold [96].
Azathioprine: The use of azathioprine has long been recog-
nized as an a etiologic factor in the development of neoplasia,
especially in the development of late non-melanoma skin
malignancies (particularly squamous cell cancer) [23, 101, 172,
173]. Furthermore, azathioprine is associated with the develop-
ment of myelodysplastic syndrome [106].
Mycophenolate mofetil: Some patient studies have sug-
gested that the risk of developing malignancies is decreased
with the use of mycophenolate mofetil [107, 174, 175], while
other studies could not demonstrate a reduction in cancer inci-
dence with mycophenolate- versus non-mycophenolate-based
therapy [174]. An SRTR analysis reported that the introduction
of mycophenolate mofetil was associated with the greatest
decrease in relative risk for the development of PTLD [14]. When
patient outcomes during different eras of immunosuppression
were compared, the use of MMF was also found to be associated
with a reduction in the incidence of PTLD [9, 174, 176]. In
patients, the principal anti-tumour mechanism associated with
mycophenolate mofetil use may be due to the decreased inci-
dence of AR.
mTOR inhibitors: While for most classes of immunosuppres-
sive agents there is a dose-dependent relationship between the
dosage of the immunosuppressive agent and secondary malig-
nancies, this does not hold true for mTOR inhibitors such as
sirolimus and everolimus. In humans, evidence suggests that
sirolimus may confer a decreased risk of malignancy compared
with other immunosuppressive medications [101, 133, 177–181].
Case reports and case series have reported that in renal trans-
plant recipients with Kaposi sarcoma, switching from cyclo-
sporine to sirolimus resulted in total resolution of the Kaposi
sarcoma [179, 182, 183]. In the TUMORAPA study, where patients
with a history of squamous cell carcinoma were studied, con-
version to sirolimus significantly reduced the risk for relapse
when compared with those who were maintained on
calcineurin inhibitor–based therapy [184]. For non-melanoma
skin cancer, Campbell et al. [185] reported that conversion to
sirolimus after 1-year post-transplant resulted in a lower yearly
incidence rate of non-melanoma skin cancer and also a lower
incidence of new or recurrent non-melanoma skin cancer.
Individual studies regarding the incidence of cancer associated
with the use of sirolimus have been conflicting [177, 186–193]. In
a study linking the US SRTR database with 15 population-based
cancer registries and national pharmacy claims, cancer inci-
dence in 32 604 sirolimus-exposed and sirolimus non-exposed
kidney transplant recipients was studied. The incidence of pros-
tate cancer was higher during sirolimus use (hazard ratio 1.86),
while the incidence of other cancers was similar or lower, with
a 26% decrease in overall cancer incidence excluding prostate
carcinoma (hazard ratio 0.74). The authors postulate that the
increase in prostate cancer diagnosis is due to sirolimus, effects
on screen detection. In addition, two meta-analyses have been
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published demonstrating a lower overall cancer incidence with
the use of sirolimus [133, 194]. In the meta-analysis of Knoll
et al. [133], including 21 randomized controlled trials with
patient-level data from 5876 patients, it was demonstrated that
sirolimus was associated with a 40% reduction in malignancy
risk and a 56% reduction in the risk of non-melanoma skin cancer
(0.44, 0.30 to 0.63) compared with controls. This effect is restricted
to patients converting to sirolimus from another immunosup-
pressive regimen, as analysis of de novo sirolimus trials revealed
no difference in malignancy risk between sirolimus and controls
[133]. Moreover, in a study analyzing Medicare claims data for
transplant recipients, de novo use of sirolimus was associated
with a 22% increased risk of PTLD [195]. Remarkably, in the meta-
analysis of Knoll et al. [133], the decreased risk of cancer develop-
ment was associated with an increased overall mortality risk due
to cardiovascular and infection-related deaths. The authors spec-
ulate that increased sirolimus-induced cardiovascular risk factors
(anaemia, proteinuria, hyperglycaemia and hyperlipidemia) and
overimmunosuppression with sirolimus might have contributed
to these findings [133]. Based on these studies, universal siroli-
mus use in kidney transplant recipients cannot be recommended
at this time.
Belatacept: For the co-stimulation blocker belatacept, an
inhibitor of T cell proliferation, PTLD risk appears similar to that
seen under calcineurin inhibitor therapy [196], however, belata-
cept is contraindicated in EBV-seronegative recipients. Although
initially a number of PTLDs of the central nervous system were
reported in patients treated with belatacept [197, 198], follow-up
data of both the BENEFIT study and, more recently, a Phase 2
study where low immunologic risk patients were switched from
calcineurin inhibitor therapy to belatacept showed a mild albeit
small increase in post-transplant malignancies [199–202].
Screening
Since cancer before transplantation increases the risk of post-
transplant malignancy, guidelines have been developed outlining
waiting times for different types and stages of cancer (Table 3).
A systematic review by Batabyal et al. [207] concluded that none
of the available recommendations are backed by strong evidence.
We recommend seeking an expert oncologist’s opinion regarding
cancer-free survival, patient life expectancies and optimal cancer
surveillance. Clinicians have to realize that even longer waiting
times do not eliminate the risk for cancer recurrence and cancer-
related death [57]. In a Swedish population-based cohort of solid
organ transplant recipients, the increased rate of death was
greatest for patients with waiting times of 5 years but persisted
with waiting times of >10 years among recipients with prior
aggressive cancer types (gastrointestinal, breast, kidney/
urothelial and hematologic malignancies) [57].
The optimal cancer screening strategy to detect post-
transplant cancers in an early stage is not defined (Table 4). In
general, many experts recommend using general practice guide-
lines in kidney transplant recipients [208–215]. Several centres
routinely screen for native kidney cancer, as the risk for kidney
cancer is greatly increased in both the dialysis and kidney trans-
plant populations [3, 4, 16–23, 216, 217]. In a medical decision
analysis, screening for kidney cancer in all transplant recipients
would have a small benefit at relatively high cost [218]. However,
directed screening using ultrasound in those with documented
acquired cystic kidney disease or those with a previous cancer in
a contralateral kidney might be cost effective. Modelling studies
by Wong et al. [219, 220] suggest that screening for colon and cer-
vical cancer would be cost effective in the kidney transplant
population. In a population-based cohort of Ontario between
1997 and 2010, 77.5, 69.8 and 91.4% of eligible solid organ trans-
plant recipients were not up to date with colorectal, cervical and
breast cancer screening, respectively [221]. Solid organ transplant
recipients with fewer co-morbidities, assessment by a primary
care provider and continuity of care by a transplant specialist at a
transplant centre were associated with higher rates of becoming
screen up to date in this study [221].
Treatment of post-transplant cancer
In general, a reduction in immunosuppression is recommended
or kidney transplant recipients upon cancer diagnosis. In the
above-mentioned study of Yanik et al. [56], it was noted that the
incidence of infection-related cancers was higher and the inci-
dence of ESRD-related cancers was lower during kidney function
intervals (time on immunosuppression), suggesting that a reduc-
tion of immunosuppression affects different cancer types differ-
ently. Similar findings were reported by van Leeuwen et al. [222],
who performed a population-based retrospective cohort study
and compared the cancer incidence in kidney transplant recipi-
ents during periods of transplant function (and immunosuppres-
sion) and after transplant failure (when immunosuppression is
Table 3. Recommendations for waiting times after cancer [203–206]
Decisions regarding waiting time should be individualized and it
should be expalined to all patients with a history of cancer that
they are at increased risk of de novo malignancy post-transplanta-
tion. Recommended waiting periods before transplantation do not
guarantee no recurrence of malignancy after transplantation
Absolute contraindication for transplantation
• Uncontrolled or untreated malignancies
• Multiple myeloma
• Advanced breast cancer (Stage III or IV)
• Colorectal cancer (Stage D)
• Advanced prostate cancer (Grade 4 or 5, T3c, T4, Nþ, Mþ)
No waiting time
• Superficial bladder cancer
• Non-metastatic, basal cell carcinoma
• Prostatic cancer microscopic (focal, microscopic low-grade
(Gleason’s grade 3), low risk) (T1a, T1c) disease
• Incidentally discovered T1 renal cell carcinoma (with no suspi-
cious histological features)
• Monoclonal gammopathy of undetermined significance
2-year waiting time
• Invasive bladder cancer
• In situ breast cancer
• Localized cervical cancer
• Duke’s Stage A and B1 colorectal cancer
• Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, post-trans-
plant lymphoproliferative disorder, leukaemia
• In situ melanoma
• Lung cancer
• Prostatic cancer
• Testicular cancer
• Thyroid cancer
• Wilm’s tumour (a 1-year waiting period might be acceptable)
5-year waiting time
• Stage II breast cancer
• Extensive cervical cancer and non-in situ cancer of the uterus
• Colorectal cancer Stage C
• Melanoma
• Large or invasive or symptomatic renal cell carcinoma
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ceased or reduced) [222]. The SIRs for NHL, lip cancer and mela-
noma were significantly elevated during periods of transplant
function. For leukaemia and lung carcinoma, SIRs remained ele-
vated after transplant failure, while the SIRs for kidney/urinary
tract and thyroid cancers significantly increased after transplant
failure. These data suggest that while the effect of immunosup-
pression on cancer risk is rapidly reversible for some cancers
(mainly infectious-related cancers), this does not hold true for
other cancer types (ESRD-related cancers) [222]. Some centres
convert patients with non-melanoma skin cancer to mTOR ther-
apy, as randomized clinical trials have shown fewer skin cancers
in mTOR-treated patients [184, 185]. Also, for other solid and
hematologic cancers, mTOR inhibitors have had marginal
success [223, 224]. However, routine conversion to mTOR inhibi-
tors to improve outcomes in all cancers or to prevent long-term
cancer development in all solid organ transplant recipients is not
widely practiced at this time, as data are lacking to support this
practice.
Outcome
Data suggest that cancer as a cause of death is on the rise. For
example, in Australia and New Zealand, cardiovascular deaths
are decreasing while cancer mortality is increasing [1].
Malignancy accounts for 8–10% of all deaths in the USA (2.6
deaths/1000 patient-years) and >30% of deaths in Australia (5/
1000 patient-years) [1, 2]. The data regarding standardized mor-
tality rates (SMRs) have been conflicting. While some studies
have suggested that the cancer-related SMR has increased with
the same magnitude as the SIR in transplant recipients [224],
other studies have shown a more nuanced picture [5]. In a study
from Hong Kong, the cancer SIR and SMR in kidney transplant
recipients were very similar (2.9 and 2.3, respectively) [225]; high
SMRs were associated with lymphoma, leukaemia, kidney,
colon, lung, bladder, melanoma and stomach cancers, while
lymphoma, liver, colorectal and lung were associated with
excess absolute risk of >25 deaths/100 000 patient-years [225].
In a US registry analysis by Kiberd et al. [5], no overall excess
mortality was observed in kidney transplant recipients.
Cancer SMRs varied substantially with age group; cancer SMRs
were 23-fold and 4.4-fold higher in patients <20 years and 20–
39 years of age, respectively, while cancer SMRs were lower in
patients >60 years of age [5]. The cancer death rates were >500/
100 000 patient-years for patients >60 years of age compared
with 13/100 000 patient-years for patients 20–39 years of age [5].
So in older patients who are at the highest risk to die from can-
cer, there is no increased risk to die from cancer in kidney trans-
plant recipients. More specific data are available concerning
post-transplant lymphoma. The 1-year survival in cadaveric
kidney transplant recipients developing lymphoma was 60%
and showed little improvement over the study period, while the
5-year survival was 40% [30]. Interestingly, in this analysis the
time of lymphoma development after transplantation did not
influence survival: 5-year survival in kidney transplantation
with lymphoma development <90 days post-transplant and
>365 days post-transplant was 41.4% and 37.0%, respectively
[30]. Post-transplant lymphoma with lymph node involvement
had a good prognosis while disseminated disease had a poor
prognosis [30].
Conclusion
Malignancy is one of the most common causes of death in kid-
ney transplant recipients. In general, the cancer incidence inT
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solid organ transplant recipients is increased 2- to 3-fold com-
pared with the general population [3, 4]. Moreover, cancer-
related mortality rates are also higher in solid organ transplant
recipients compared with the general population [5]. Several
risk factors for post-transplantation cancer development have
been identified and immunosuppression is considered the most
important risk factor, as it decreases the immunologic control
of oncogenic viral infection and immunosurveillance. Currently
available immunosuppressive agents influence different anti-
cancer pathways and mTOR inhibitors seem to have a
favourable profile in this respect. However, the increased mor-
tality associated with mTOR inhibitor use in a recent meta-
analysis argues against their universal use in renal allograft
recipients or switching to mTOR inhibition in all patients with
post-transplant malignancies. Intense collaboration between
nephrologists and oncologists is needed in this field to design
safer immunosuppressive regimens and define optimal screen-
ing and treatment strategies in kidney transplant recipients.
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